Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

The yin and yang-like clinical implications of the cdkn2a/arf/cdkn2b gene cluster in acute lymphoblastic leukemia

  • González Gil, Celia|||0000-0002-7582-1482
  • Ribera Salas, Jordi|||0000-0003-4796-6470
  • Ribera, Jose-Maria|||0000-0003-1042-6024
  • Genescà, Eulàlia|||0000-0002-5657-4842
Acute lymphoblastic leukemia (ALL) is a malignant clonal expansion of lymphoid hematopoietic precursors that exhibit developmental arrest at varying stages of differentiation. Similar to what occurs in solid cancers, transformation of normal hematopoietic precursors is governed by a multistep oncogenic process that drives initiation, clonal expansion and metastasis. In this process, alterations in genes encoding proteins that govern processes such as cell proliferation, differentiation, and growth provide us with some of the clearest mechanistic insights into how and why cancer arises. In such a scenario, deletions in the 9p21.3 cluster involving CDKN2A/ARF/CDKN2B genes arise as one of the oncogenic hallmarks of ALL. Deletions in this region are the most frequent structural alteration in T-cell acute lymphoblastic leukemia (T-ALL) and account for roughly 30% of copy number alterations found in B-cell-precursor acute lymphoblastic leukemia (BCP-ALL). Here, we review the literature concerning the involvement of the CDKN2A/B genes as a prognosis marker of good or bad response in the two ALL subtypes (BCP-ALL and T-ALL). We compare frequencies observed in studies performed on several ALL cohorts (adult and child), which mainly consider genetic data produced by genomic techniques. We also summarize what we have learned from mouse models designed to evaluate the functional involvement of the gene cluster in ALL development and in relapse/resistance to treatment. Finally, we examine the range of possibilities for targeting the abnormal function of the protein-coding genes of this cluster and their potential to act as anti-leukemic agents in patients.
Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

The Secondary Myelodysplastic Neoplasms (MDS) Jigsaw

  • Calvete, Oriol|||0000-0002-2623-2876
  • Mestre, Julia|||0000-0002-4809-3897
  • Jerez, Andrés|||0000-0002-2079-6638
  • Sole, F|||0000-0002-3251-2161
There is a great deal of controversy in the hematologic community regarding the classification of secondary myelodysplastic neoplasms (MDSs). Current classifications are based on the presence of genetic predisposition and MDS post-cytotoxic therapy (MDS-pCT) etiologies. However, since these risk factors are not exclusive for secondary MDSs and there are multiple overlapping scenarios, a comprehensive and definitive classification is yet to come. In addition, a sporadic MDS might arise after a primary tumor fulfills the diagnostic criteria of MDS-pCT without a causative cytotoxicity. In this review, we describe the triggering pieces of a secondary MDS jigsaw: previous cytotoxic therapy, germline predisposition and clonal hematopoiesis. Epidemiological and translational efforts are needed to put these pieces together and ascertain the real weight of each of these pieces in each MDS patient. Future classifications must contribute to understanding the role of secondary MDS jigsaw pieces in different concomitant or independent clinical scenarios associated with the primary tumor.
Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

A framework for the clinical implementation of optical genome mapping in hematologic malignancies

  • Levy, Brynn|||0000-0002-4213-3480
  • Kanagal-Shamanna, Rashmi|||0000-0001-7829-5249
  • Sahajpal, Rashmi Kanagal
  • Neveling, Nikhil S.
  • Rack, Katrina
  • Dewaele, Barbara|||0000-0002-1183-5228
  • Olde Weghuis, Daniel
  • Stevens-Kroef, Marian
  • Puiggros, Anna|||0000-0001-9627-4978
  • Mallo, Maria del Mar|||0000-0001-7741-498X
  • Clifford, Benjamin
  • Mantere, Tuomo
  • Hoischen, Alexander
  • Espinet Solà, Blanca|||0000-0002-4294-8145
  • Kolhe, Ravindra|||0000-0002-8283-2403
  • Sole, F.|||0000-0002-3251-2161
  • Raca, Gordana|||0000-0002-3521-9585
  • Smith, Adam C.|||0000-0001-9927-4914
Optical Genome Mapping (OGM) is rapidly emerging as an exciting cytogenomic technology both for research and clinical purposes. In the last 2 years alone, multiple studies have demonstrated that OGM not only matches the diagnostic scope of conventional standard of care cytogenomic clinical testing but it also adds significant new information in certain cases. Since OGM consolidates the diagnostic benefits of multiple costly and laborious tests (e.g., karyotyping, fluorescence in situ hybridization, and chromosomal microarrays) in a single cost-effective assay, many clinical laboratories have started to consider utilizing OGM. In 2021, an international working group of early adopters of OGM who are experienced with routine clinical cytogenomic testing in patients with hematological neoplasms formed a consortium (International Consortium for OGM in Hematologic Malignancies, henceforth "the Consortium") to create a consensus framework for implementation of OGM in a clinical setting. The focus of the Consortium is to provide guidance for laboratories implementing OGM in three specific areas: validation, quality control and analysis and interpretation of variants. Since OGM is a complex technology with many variables, we felt that by consolidating our collective experience, we could provide a practical and useful tool for uniform implementation of OGM in hematologic malignancies with the ultimate goal of achieving globally accepted standards.